

FH/FHR-1

HK342

Edition 05-26

**ELISA KIT
PRODUCT INFORMATION & MANUAL**

Read carefully prior to starting procedures!

For use in laboratory research only

Not for clinical or diagnostic use



Note that this user protocol is not lot-specific and is representative for the current specifications of this product. Please consult the vial label and the Certificate of Analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

TABLE OF CONTENTS

	Page
1. Intended use	2
2. Introduction	2
3. Kit features	2
4. Protocol overview	4
5. Kit components and storage instructions	5
6. Warnings and precautions	6
7. Sample preparation	7
8. Reagent preparation.....	8
9. ELISA protocol	9
10. Interpretation of results	10
11. Technical hints.....	10
12. Quality control.....	11
13. Performance characteristics	11
14. Troubleshooting	12
15. References	13

1. INTENDED USE

The FH/FHR-1 ELISA kit is intended for the in vitro quantitative determination of FH/FHR-1 in serum, plasma, and urine samples. This kit is for laboratory research use only and is not for use in diagnostic or therapeutic procedures.

The analysis should be performed by trained laboratory professionals.

2. INTRODUCTION

The complement system is a key component of the immune response that defends against infections, initiates inflammation, manages immune complexes and regulation of immune responses. Complement factor H (CFH or FH) is the principal regulator of the alternative pathway, ensuring that complement activation is restricted to appropriate targets. Unlike the classical and lectin pathways, the alternative pathway is constitutively active at a low level and therefore requires tight control. CFH exerts this control by binding to C3b, accelerating decay of the C3 convertase (C3bBb), and acting as a cofactor for Complement factor I-mediated cleavage of C3b. In addition, CFH inhibits convertase formation by competing with factor B. Through these mechanisms, it regulates complement both in fluid phase and on host cell surfaces.

Structurally, CFH is a ~150 kDa plasma glycoprotein composed of linearly arranged 20 short consensus repeat (SCR) domains (also called complement control protein (CCP) modules). These domains confer multiple ligand-binding sites, including three regions for C3b and several for polyanions such as glycosaminoglycans. Functionally, CFH is organized into two main regions: the N-terminal SCR1–4 domains mediate complement regulatory activity, while the C-terminal domains, particularly SCR19–20 with contribution from SCR7, enable recognition of host surfaces via binding to C3 fragments and polyanions. This dual architecture allows CFH to selectively protect self-tissues from complement-mediated damage.

CFH is part of a protein family that includes the complement factor H-related (FHR) proteins (FHR1–FHR5), which share a similar SCR-based structure and high sequence homology, particularly in domains corresponding to CFH surface-recognition regions. Unlike FHL1, FHR1–5 proteins lack domains equivalent to CFH SCR1–4 and therefore generally lack intrinsic complement regulatory activity. Instead, they are thought to modulate complement by competing with CFH for ligand binding.

Complement factor H-related protein 1 shows the closest similarity to CFH. Its C-terminal domains are highly homologous to CFH SCR19–20, enabling binding to similar ligands such as C3b and polyanions. However, lacking regulatory domains, FHR1 can displace CFH from surfaces without inhibiting complement activation, potentially promoting local amplification. This competitive interaction is enhanced by FHR1 dimerization.

Dysregulation of the CFH–FHR balance is associated with diseases including Atypical hemolytic uremic syndrome, C3 glomerulopathy (aHUS), and age-related macular degeneration (AMD), highlighting the clinical importance of this regulatory network.

3. KIT FEATURES

- Working time of 2½ hours.
- Minimum concentration which can be measured is 3.9 ng/ml.
- Measurable concentration range of 3.9 to 250 ng/ml.
- Working volume of 100 µl/well.

Cross reactivity

Potential cross-reacting species detected in the human FH/FHR-1 ELISA:

Cross reactant	Reactivity
Bovine	negative
Horse	negative
Mouse	negative
Rat	negative
Monkey (Cynomolgus)	negative

Table 1

Potential cross-reacting proteins detected in the human FH/FHR-1 ELISA:

Cross reactant	Reactivity
FHR-2, recombinant	negative
FHR-3, recombinant	negative
FHR-4, recombinant	negative
FHR-5, recombinant	negative

Table 2

Cross-reactivity for other species or proteins has not been tested.

4. PROTOCOL OVERVIEW




Figure 1

- The human FH/FHR-1 ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 2½ hours.
- The efficient format of a plate with twelve disposable 8-well strips allows free choice of batch size for the assay.
- Samples and standards are incubated in microtiter wells coated with antibodies recognizing human FH/FHR-1.
- Peroxidase conjugate antibody will bind to the captured human FH/FHR-1.
- Peroxidase conjugate antibody will react with the substrate, tetramethylbenzidine (TMB).
- The enzyme reaction is stopped by the addition of oxalic acid.
- The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human FH/FHR-1 standards (log).
- The human FH/FHR-1 concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.

5. KIT COMPONENTS AND STORAGE INSTRUCTIONS

Kit component	Cat.#	Quantity HK342-01	Quantity HK342-02	Color code
Wash buffer 20x	WB21	1 vial (60 ml)	1 vial (60 ml)	Colorless
Dilution buffer 10x	DB89	1 vial (20 ml)	1 vial (20 ml)	Green
Standard		2 vials, lyophilized	4 vials, lyophilized	White
Conjugate, peroxidase-labeled		1 vial, 1 ml lyophilized	2 vials, 1 ml lyophilized	Blue
TMB substrate	TMB050/TMB100	1 vial (11 ml)	1 vial (22 ml)	Brown
Stop solution	STOP110	1 vial (22 ml)	1 vial (22 ml)	Red
12 Microtiter strips, pre-coated		1 plate	2 plates	
Certificate of Analysis		1	1	
Manual		1	1	
Data collection sheet		2	2	

Table 3

- Upon receipt, store individual components at 2 - 8°C. Do not freeze.
- Do not use components beyond the expiration date printed on the kit label.
- The standard and conjugate are stable in lyophilized form until the expiration date indicated on the kit label, if stored at 2 - 8°C.
- The exact amount of the standard is indicated on the label of the vial and the Certificate of Analysis.
- After reconstitution the standard must be used within 1 hour. The standard cannot be stored for repeated use.
- Once reconstituted conjugate is stable for 1 month if stored at 2 - 8°C.
- Upon receipt, foil pouch around the plate should be vacuum-sealed and unpunctured. Any irregularities to aforementioned conditions may influence plate performance in the assay.
- Return unused strips immediately to the foil pouch containing the desiccant pack and reseal along the entire edge of the zip-seal. Quality guaranteed for 1 month if stored at 2 - 8°C.

Materials requires but not provided

- Calibrated micropipettes and disposable tips.
- Distilled or de-ionized water.
- Plate washer: automatic or manual.
- Polypropylene tubes.
- Calibrated ELISA plate reader capable of measuring absorbance at 450 nm.
- Adhesive covers can be ordered separately. Please contact your local distributor.

6. WARNINGS AND PRECAUTIONS

- For research use only, not for diagnostic or therapeutic use.
- This kit should only be used by qualified laboratory staff.
- Do not under any circumstances add sodium azide as preservative to any of the components.
- Do not use kit components beyond the expiration date.
- Do not mix reagents from different kits and lots. The reagents have been standardized as a unit for a given lot. Use only the reagents supplied by the manufacturer.
- The assay has been optimized for the indicated standard range. Do not change the standard range.
- Open vials carefully: vials are under vacuum.
- Do not ingest any of the kit components.
- Kit reagents contain 2-chloroacetamide as a preservative. 2-Chloroacetamide is harmful in contact with skin and toxic if swallowed. In case of accident or if you feel unwell, seek medical advice immediately.
- The TMB substrate is light sensitive, keep away from bright light. The solution should be colourless until use.
- The stop solution contains 2% oxalic acid and can cause irritation or burns to respiratory system, skin and eyes. Direct contact with skin and eyes should be strictly avoided. If contact occurs, rinse immediately with plenty of water and seek medical advice.
- Incubation times, incubation temperature and pipetting volumes other than those specified may give erroneous results.
- Do not reuse microwells or pour reagents back into their bottles once dispensed.
- Handle all biological samples as potentially hazardous and capable of transmitting diseases.
- Hemolyzed, hyperlipemic, heat-treated or contaminated samples may give erroneous results.
- Use polypropylene tubes for preparation of standard and samples. Do not use polystyrene tubes or sample plates.
- The standard is of human origin. It was tested for various viruses and found negative. Since no test method can offer complete assurance that infectious agents are absent, this reagent should be handled as any potentially infectious human serum or blood specimen. Handle all materials in contact with this reagent according to guide-lines for prevention of transmission of blood-borne infections.

7. SAMPLE PREPARATION

Collection and handling

Serum or plasma

Collect blood using normal aseptic techniques. Blood samples should be kept on ice. If serum is used, separate serum from blood after clotting within 20 minutes by centrifugation (1,500xg at 4°C for 15 min). Transfer the serum to a fresh polypropylene tube.

If plasma is used, separate plasma from blood within 20 minutes after blood sampling by centrifugation (1,500xg at 4°C for 15 min). Transfer the plasma to a fresh polypropylene tube.

Most reliable results are obtained if EDTA plasma is used.

Urine

Collect urine using normal aseptic techniques. Centrifuge the urine to remove debris (1500xg at 4 °C for 15 min). Transfer urine to a fresh polypropylene tube.

Storage

Store samples below -20°C, preferably at -70°C in polypropylene tubes. Storage at -20°C can affect recovery of human FH and FHR-1. Use samples within 24 hours after thawing. Avoid multiple freeze-thaw cycles which may cause loss of human FH/FHR-1 activity and give erroneous results.

Do not use hemolyzed, hyperlipemic, heat-treated or contaminated samples.

Before performing the assay, samples should be brought to room temperature (18 – 25°C) and mixed gently. Prepare all samples (controls and test samples) prior to starting the assay procedure. Avoid foaming.

Dilution procedures

Serum or plasma samples

Human FH/FHR-1 can be measured accurately if serum or plasma samples are diluted at least 5,000x with supplied dilution buffer in polypropylene tubes.

Note that most reliable results are obtained with EDTA plasma.

Urine samples

Human FH/FHR-1 can be measured accurately if urine samples are diluted at least 4x with supplied dilution buffer in polypropylene tubes.

Comment regarding recommended sample dilution

The mentioned dilution for samples is a minimum dilution and should be used as a guideline. The recovery of human FH/FHR-1 from an undiluted sample is not 100% and may vary from sample to sample. When testing less diluted samples it is advisable to run recovery experiments to determine the influence of the matrix on the detection of human FH/FHR-1.

Do not use polystyrene tubes or sample plates for preparation or dilution of the samples.

8. REAGENT PREPARATION

Allow all the reagents to equilibrate to room temperature (20 – 25°C) prior to use. Return to proper storage conditions immediately after use.

Wash buffer

Prepare wash buffer by mixing 60 ml of 20x wash buffer with 1140 ml of distilled or de-ionized water, which is sufficient for 2 x 96 tests. Where less volume is required, prepare the desired volume of wash buffer by diluting 1 part of the 20x wash buffer with 19 parts of distilled or de-ionized water.

Dilution buffer

Prepare dilution buffer by mixing 20 ml of the 10x dilution buffer with 180 ml of distilled or de-ionized water, which is sufficient for 2 x 96 tests. Where less volume is required, prepare the desired volume of dilution buffer by diluting 1 part of the 10x dilution buffer with 9 parts of distilled or de-ionized water. Concentrated dilution buffer may contain crystals. In case the crystals do not disappear at room temperature within 1 hour, concentrated dilution buffer can be warmed up to 37°C. Do not shake the solution.

Standard solution

The standard is reconstituted with the amount of dilution buffer mentioned on the CoA in the standard vial. Use the standard vial as Tube 1 in Figure 2.

The standard cannot be stored for repeated use. Prepare each human FH/FHR-1 standard in polypropylene tubes by serial dilution of the reconstituted standard with dilution buffer as shown in Figure 2*. The standard cannot be stored for repeated use.




Figure 2

*) CoA: Certificate of Analysis, Rec. St: Reconstituted Standard, Db: Dilution buffer

Conjugate solution

The conjugate is reconstituted by pipetting 1 ml distilled or de-ionized water. Please note that, although the conjugate may appear cloudy after reconstitution, this has no effect on the test. Dilute the reconstituted 1 ml conjugate with 11 ml dilution buffer, which is sufficient for 1 x 96 tests. In case less volume is required, prepare the desired volume of conjugate by diluting 1 part of the reconstituted conjugate with 11 parts of dilution buffer.

9. ELISA PROTOCOL

Bring all reagents to room temperature (20 - 25°C) before use.

1. Determine the number of test wells required, put the necessary microwell strips into the supplied frame, and fill out the data collection sheet. Return the unused strips to the storage bag with desiccant, seal and store at 2 - 8°C.
2. Transfer 100 µl in duplicate of standard, samples, or controls into appropriate wells. Do not touch the side or bottom of the wells.
3. Cover the tray and tap the tray to eliminate any air bubbles. Be careful not to splash liquid onto the cover.
4. Incubate the strips or plate for 1 hour at room temperature.
5. Wash the plates 4 times with wash buffer as follows*:
 - a. Carefully remove the cover, avoid splashing.
 - b. Empty the plate by inverting plate and shaking contents out over the sink, keep inverted and tap dry on a thick layer of tissues.
 - c. Add 200 µl of wash buffer to each well, wait 20 seconds, empty the plate as described in 5b.
 - d. Repeat the washing procedure 5b/5c three times.
 - e. Empty the plate and gently tap on thick layer of tissues.
6. Add 100 µl of diluted conjugate to each well using the same pipetting order as applied in step 2. Do not touch the side or bottom of the wells.
7. Cover the tray and incubate the tray for 1 hour at room temperature.
8. Repeat the wash procedure described in step 5.
9. Add 100 µl of TMB substrate to each well, using the same pipetting order as applied in step 2. Do not touch the side or bottom of the wells.
10. Cover the tray and incubate the tray for 30 minutes at room temperature. It is advised to control the plate regularly. In case of strong development the TMB reaction can be stopped sooner. Avoid exposing the microwell strips to direct sunlight. Covering the plate with aluminum foil is recommended.
11. Stop the reaction by adding 100 µl of stop solution with the same sequence and timing as used in step 12. Mix solutions in the wells thoroughly by gently swirling the plate. Gently tap the tray to eliminate any air bubbles trapped in the wells.
12. Read the plate within 30 minutes after addition of stop solution at 450 nm using a plate reader, following the instructions provided by the instrument's manufacturer.

*) In case plate washer is used, please note: use of a plate washer can result in higher background and decrease in sensitivity. We advise validation of the plate washer with the manual procedure. Make sure the plate washer is used as specified for the manual method.

10. INTERPRETATION OF RESULTS

- Calculate the mean absorbance for each set of duplicate standards, control and samples.
- If individual absorbance values differ by more than 15% from the corresponding mean value, the result is considered suspect and the sample should be retested.
- The mean absorbance of the zero standard should be less than 0.3.
- Create a standard curve using computer software capable of generating a good curve fit. The mean absorbance for each standard concentration is plotted on the vertical (Y) axis versus the corresponding concentration on the horizontal (X) axis (logarithmic scale).
- If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
- If the mean absorbance of samples exceeds that of the highest standard concentration, they fall outside the assay's range. Such samples ought to be reanalysed using a greater dilution factor.

11. TECHNICAL HINTS

- User should be trained and familiar with ELISA assays and test procedure.
- If user is not familiar with the ELISA technique it is recommended that the user perform a pilot assay prior to evaluation of your samples. Perform the assay with a standard curve only following the instructions.
- Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Completely empty wells before dispensing wash buffer, fill with wash buffer as indicated for each cycle and do not allow wells to sit uncovered or dry for extended periods.
- Since exact conditions may vary from assay to assay, a standard curve must be established for every run. Samples should be referred to the standard curve prepared on the same plate.
- Do not mix reagents from different batches, or other reagents and strips. Remainders should not be mixed with contents of freshly opened vials.
- Each time the kit is used, fresh dilutions of standard, sample, conjugate and buffers should be made.
- Caps and vials are not interchangeable. Caps should be replaced on the corresponding vials.
- To avoid cross-contaminations, change pipette tips between reagent additions of each standard, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.
- Waste disposal should be performed according to your laboratory regulations.

Technical support

Do not hesitate to contact our technical support team at support@hycultbiotech.com for inquiries and technical support regarding the human Factor H ELISA.

Hycult Biotech, Frontstraat 2A, 5405 PB Uden, the Netherlands

T: +31 (0)413 251 335, F: +31 (0)413 248 353

12. QUALITY CONTROL

The Certificate of Analysis included in this kit is lot-specific and is to be used to verify results obtained by your laboratory. The absorption values provided on the certificate of analysis are to be used as a guideline only. The results obtained by your laboratory may differ.

This assay is designed to eliminate interference by soluble receptors, binding proteins, and other factors present in biological samples. Until all factors have been tested in the immunoassay, the possibility of interference cannot be excluded.

For optimal performance of this kit, it is advised to work according to good laboratory practice.

13. PERFORMANCE CHARACTERISTICS

Adaptation of standard using Dr. Opperman values converted to Dr. Morgan values

Six EDTA plasma donors were tested using the Opperman standard (3.9 – 250 ng/ml) or the Morgan standard (0.9 – 59.6 ng/ml). The resulting FH/FHR-1 values of the 6 donor EDTA samples are expressed in Opperman and in Morgan standard mg/ml values .

EDTA plasma donor	[FH/FHR-1] mg/ml Opperman	[FH/FHR-1] mg/ml Morgan
Donor 1	0.73	0.17
Donor 2	1.17	0.28
Donor 3	1.22	0.29
Donor 4	0.57	0.14
Donor 5	0.26	0.06
Donor 6	0.71	0.18

Table 4

Recovery

Normal human blood samples (plasma), containing baseline levels of human FH/FHR-1, were spiked with FH/FHR-1 in concentrations of 50 and 100 ng/ml. Samples with and without human FH/FHR-1 were incubated for 1 hour at room temperature. Samples were measured using the ELISA. Values for human FH/FHR-1 ranged between 96% and 108% (mean 102%).

14. TROUBLESHOOTING

Warranty claims and complaints in respect of deficiencies must be logged before expiry date of the product. A written complaint containing lot number of the product and experimental data shall be sent to support@hycultbiotech.com. Suggestions summarized below in Table 5 can be used as guideline in case of unexpected assay results.

Low absorbance	High absorbance	Poor duplicates	All wells positive	All wells negative	Possible cause
•	•		•	•	Kit materials or reagents are contaminated or expired
•					Incorrect reagents used
•		•	•		Lyophilized reagents are not properly reconstituted
•	•	•	•	•	Incorrect dilutions or pipetting errors
•		•			Improper plastics used for preparation of standard and/or samples
•	•				Improper incubation times or temperature
		•			Especially in case of 37°C incubation: plates are not incubated uniformly
•					Assay performed before reagents had reached room temperature
•	•	•	•	•	Procedure not followed correctly
		•		•	Omission of a reagent or a step
		•			Poor mixing of samples
	•		•		Low purity of water
	•	•			Strips were kept dry for too long during/after washing
	•	•	•		Inefficient washing
	•	•			Cross-contamination from other samples or positive control
		•	•		TMB solution is not clear or colourless
•	•				Wrong filter in the microtiter reader
	•	•			Airbubbles
		•			Imprecise sealing of the plate after use
•					Wrong storage conditions
•					Lamp in microplate reader is not functioning optimally

Table 5

15. REFERENCES

1. Oppermann, M. et al; Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays. *J Immunol Methods* 1990, *133*: 181
2. Oppermann M. et al; Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure. *Kidney Int* 1991, *40*: 939
3. Pickering M. et al: Renal diseases associated with complement factor H: novel insights from humans and animals. *Clin Exp Immunol* 1993, *151*: 210
4. Scambi, C et al; Comparative Proteomic Analysis of Serum from Patients with Systemic Sclerosis and Sclerodermatous GVHD. Evidence of Defective Function of Factor H. *PlosOne* 2010, *5*:e12162
5. Brandstätter, H et al; Purification and biochemical characterization of functional complement factor H from human plasma fractions. *Vox Sanguinis* 2012
6. Lv, M et al. (2013) Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation. *PLoS ONE* 8(3): e58735
7. Wu, J et al; Altered Expression of Sialylated Glycoproteins in Ovarian Cancer Sera Using Lectin-based ELISA Assay and Quantitative Glycoproteomics Analysis. *J of Proteome* 2013, *12*:3342
8. Nagamachi, S et al; Properdin has an ascendancy over factor H regulation in complement-mediated renal tubular damage. *BMC Nephrology* 2014, *15*:82
9. Scambi, C et al; The Local Complement Activation on Vascular Bed of Patients with Systemic Sclerosis: A Hypothesis-Generating Study. *PLoS One* 2015, *10*: e0114856